VisionCare Ophthalmic Technologies Announces Presentations at the American Society of Cataract and Refractive Surgery Annual Meeting
Telescope Prosthesis for End-Stage Macular Degeneration Highlighted in
SARATOGA, Calif., April 25 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), announced today two presentations on its platform technology are scheduled at the upcoming annual symposium of the American Society of Cataract and Refractive Surgery (ASCRS) April 27 - May 2, 2007, in San Diego. Podium presentations are scheduled at the San Diego Convention Center as follows: Sunday, April 29 Session: ASCRS Paper Session 2-A: RETINA ARMD, CME, ROP Location: RM 24 C 8:12 AM Two-Year Results of an Implantable Telescope in Patients with End-Stage Macular Degeneration R. Doyle Stulting, MD, PhD, Emory Eye Center, Emory University, Atlanta 8:22 AM Surgical Placement of an Implantable Telescope in Patients with End-Stage ARMD Kathryn Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston At ASCRS, VisionCare is located in Booth #2940 at the San Diego Convention Center. About the Telescope Prosthetic Device The investigational Implantable Miniature Telescope (IMT(TM) by Dr. Isaac Lipshitz) is designed to be a permanent solution for moderate to profound vision loss due to advanced, end-stage forms of AMD that have no current surgical or medical treatment options. Smaller than a pea, the telescope prosthetic device is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation. The prospective, multicenter IMT002 Phase II/III trial was designed to evaluate the safety and efficacy of VisionCare's investigational medical device in individuals with moderate to profound bilateral central vision impairment associated with end-stage AMD. The trial enrolled over 200 patients at 28 leading medical universities and ophthalmic centers across the country. VisionCare has filed a Premarket Approval (PMA) application amendment for the telescope prosthesis. The submission seeks marketing approval for the treatment of central vision loss due to advanced, irreversible forms of AMD. To date, no additional clinical investigations have been requested. Assuming no significant additional analyses or clinical data are required, the Company projects regulatory approval in the second half of 2007. About Macular Degeneration Macular degeneration is a disorder of the central retina, or macula, which is responsible for detailed vision that controls important functional visual activities like reading, recognizing faces, and watching television. According to the National Eye Institute over 1.7 million Americans over age 50 suffer mild to profound vision loss from advanced AMD, which frequently culminates as end-stage AMD (visual impairment due to untreatable advanced AMD). Patients affected in both eyes often experience a loss of independence, social interaction, and have difficulty with activities of daily living requiring detailed vision. Approximately half of the individuals living with advanced AMD are affected in both eyes. About VisionCare VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA is a privately-held company focused on development, manufacturing, and marketing of visual prosthetic devices. The Implantable Miniature Telescope was invented by company founders, Isaac Lipshitz, M.D., and Yossi Gross. Information on VisionCare can be found at www.visioncareinc.net.
SOURCE VisionCare Ophthalmic Technologies, Inc.
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.